Adeno-associated virus screening method
The method uses an adsorbent with immobilized AAV-binding protein to screen AAV mutants efficiently, addressing the complexity of conventional screening methods by enabling easy characterization of AAV mutants based on their properties.
Patent Information
- Application Number
- JP2023111963
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2023-07-07
- Publication Date
- 2024-12-06
AI Technical Summary
Conventional methods for screening adeno-associated viruses (AAV) with desired characteristics are complex and require purification and infection experiments, lacking a simple and efficient screening technique.
A method involving the use of an adsorbent containing an insoluble carrier with an AAV-binding protein immobilized on it, allowing for the analysis and screening of AAV mutants based on their properties without purification, through adsorption and elution steps.
Enables easy screening of AAV mutants with desired characteristics, particularly in terms of cell infectivity, by simplifying the process and eliminating the need for purification and infection experiments.
Smart Images

Figure 2024170270000001 
Figure 2024170270000002 
Figure 2024170270000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for screening adeno-associated viruses (AAV), and in particular to a method that enables simple screening of AAVs having desired properties. [Background technology]
[0002] Adeno-associated virus (AAV) is a non-enveloped virus classified in the Parvoviridae family and Dependovirus genus. The AAV envelope particle is composed of three types of proteins (VP1, VP2, and VP3), and is formed by mixing and assembling approximately 60 protein molecules in a ratio of VP1:VP2:VP3 = 1:1:10, resulting in a regular icosahedral shape with a diameter of 20 to 30 nm.
[0003] AAV is capable of infecting the cells of a wide range of species, including humans, and can also infect non-dividing cells that have completed differentiation, such as blood cells, muscle, and nerve cells. It is not pathogenic to humans, so there is little risk of side effects. In addition, the viral particles are physicochemically stable. For these reasons, AAV is attracting attention as a vector for gene transfer to treat congenital genetic diseases.
[0004] By substituting amino acid residues at specific positions in the polypeptides that constitute the AAV protein with other amino acid residues, it is possible to obtain AAV mutants with altered AAV properties. As an example, Non-Patent Document 1 discloses AAV mutants that have a different ability to infect cells compared to AAV with unsubstituted amino acid residues (wild-type AAV).
[0005] Such a screening technique based on the characteristics of AAV is essential for promoting research and development of gene therapy using AAV. However, the conventional technique requires purification of the expressed AAV mutant and infection experiment of the purified AAV mutant into cultured cells, which is very complicated. Therefore, a simple screening technique for the above characteristics has been required. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Lochrie, MA, et al., Journal of virology, 80(2), 821, 2006 Summary of the Invention [Problem to be solved by the invention]
[0007] An object of the present invention is to provide a method for easily screening for adeno-associated viruses having desired characteristics. [Means for solving the problem]
[0008] As a result of extensive research, the inventors discovered that by analyzing an adeno-associated virus (AAV) mutant library using an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the carrier, it is possible to screen the mutants based on the characteristics of the mutants without purifying the mutants themselves, and thus completed the present invention.
[0009] That is, the present invention includes the following aspects [1] to [4].
[0010] [1] A step of introducing mutations into a polynucleotide encoding an AAV protein to construct a library of said polynucleotide variants; Culturing a transformant obtained by transforming a host with the library to express the AAV mutant; and analyzing the characteristics of the AAV mutant, The analyzing step includes a step of adsorbing the AAV mutant to an AAV adsorbent comprising an insoluble carrier and an AAV binding protein immobilized on the carrier; The method comprises at least a step of eluting the AAV mutant adsorbed to the adsorbent using an elution solution.
[0011] [2] The property is the ability to infect cells; The method according to the above-mentioned [1], wherein the AAV binding protein is a polypeptide selected from any one of the following (i) to (iii): (i) a polypeptide comprising at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or the amino acid residues from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1; (ii) A polypeptide having an amino acid sequence including at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, with the proviso that these amino acid residues include substitution, deletion, insertion, or addition of one or several amino acid residues at one or several positions, and having AAV-binding activity; (iii) A polypeptide comprising at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or the amino acid residues from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, and having 70% or more homology to an amino acid sequence consisting of these amino acid residues, and having AAV-binding activity.
[0012] [3] The method according to [2] above, wherein the AAV binding protein is a polypeptide selected from any one of the following (iv) to (vi): (iv) a polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO:1; (v) a polypeptide having an amino acid sequence including at least the amino acid residues from serine at position 312 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid sequence includes substitution, deletion, insertion, or addition of one or several amino acid residues at one or several positions within the amino acid residues at positions 312 to 500, and having AAV binding activity; (vi) A polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO:1, and having 70% or more identity to the amino acid sequence consisting of the amino acid residues at positions 312 to 500, and having AAV-binding activity.
[0013] [4] The method according to any one of [1] to [3] above, wherein the AAV adsorbent is in the form of a column packed with the adsorbent. Effect of the Invention
[0014] The present invention is a method for screening AAV, which includes the steps of constructing a library of polynucleotide variants by mutagenizing a polynucleotide encoding an adeno-associated virus (AAV) protein, culturing a transformant obtained by transforming a host with the library to express AAV variants, and analyzing the properties of the AAV variants, and is characterized in that the analyzing step includes at least the steps of adsorbing the AAV variants to an AAV adsorbent comprising an insoluble carrier and an AAV binding protein immobilized on the carrier, and eluting the AAV variants adsorbed to the adsorbent with an elution solution.Compared to conventional screening methods that require purification of the expressed AAV variants and an infection experiment of the purified AAV variants into cultured cells, this method allows for simple screening of AAV variants with desired properties.
[0015] In particular, when the AAV-binding protein is a polypeptide containing at least an amino acid sequence corresponding to the extracellular domain 1 or domain 2 of KIAA0319L, analysis can be performed based on the difference in the ability to infect cells. Therefore, compared with conventional screening methods, AAV mutants having the ability to infect desired cells can be screened more simply. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] The present invention will be described in detail below.
[0017] In the present invention, AAVs having desired properties are screened for by a method comprising at least the following steps (A) to (C). (A) A step of introducing mutations into a polynucleotide encoding an AAV protein to construct a library of said polynucleotide variants (hereinafter also referred to as the "library construction step"). (B) A step of culturing a transformant obtained by transforming a host with the library constructed in the step (A) and expressing an AAV mutant (hereinafter also referred to as a "mutant expression step"). (C) A step of analyzing the characteristics of the AAV mutant expressed in step (B) (hereinafter also referred to as the "characteristics analysis step"). Each step will be described in detail below.
[0018] (A) Library construction process Mutations can be introduced into a polynucleotide encoding an AAV protein by, for example, a method commonly used by those skilled in the art. One example is mutations using error-prone PCR. The reaction conditions in error-prone PCR are not particularly limited as long as they can introduce desired mutations into a polynucleotide encoding an AAV protein. For example, mutations can be introduced into a polynucleotide by making the concentrations of the four types of substrate deoxynucleotides (dATP / dTTP / dCTP / dGTP) non-uniform and adding MnCl2 at a concentration of 0.01 mM to 10 mM (preferably 0.1 mM to 2 mM) to the PCR reaction solution and performing PCR. As another example, a nucleotide mutation can be selectively introduced into a specific site of a sequence by performing PCR using a primer in which a mixed base is introduced into a part of the sequence. Examples of methods for introducing mutations other than the above examples include a method of introducing a mutation into a polynucleotide encoding the entire or partial sequence of an AAV protein by contacting and acting a mutagenic agent on the polynucleotide or irradiating it with ultraviolet light. In the above-mentioned method, the mutagen used may be any mutagenic agent commonly used by those skilled in the art, such as hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine, nitrous acid, sulfurous acid, or hydrazine.
[0019] The library to be constructed may be the polynucleotide variant itself mutated by the method described above, but it is more preferable that the polynucleotide variant is inserted at an appropriate position in an expression vector (e.g., a bacteriophage, cosmid, or plasmid normally used for transformation of prokaryotic or eukaryotic cells). The expression vector is not particularly limited as long as it can stably exist and replicate in the host to be transformed. The appropriate position means a position that does not destroy the replication function of the expression vector, the desired antibiotic marker, or the region involved in transmissibility. When the polynucleotide variant is inserted into the expression vector, it is preferable to insert it in a state where it is linked to a functional polynucleotide such as a promoter required for expression.
[0020] (B) Mutant expression process To obtain a transformant capable of expressing an AAV mutant from the library constructed in (A), a host may be transformed by a method commonly used by those skilled in the art. There are no particular limitations on the host, and examples include animal cells (CHO (Chinese Hamster Ovary) cells, HEK cells, HeLa cells, COS cells, etc.) and insect cells (Sf9, Sf21, etc.). There are also no particular limitations on the method for expressing an AAV mutant from the transformant, and the expression may be performed under culture and expression conditions suitable for the host and expression vector.
[0021] (C) Characteristic analysis process The present invention relates to a process comprising the steps of: A step of adsorbing the AAV mutant to an AAV adsorbent comprising an insoluble carrier and an AAV binding protein immobilized on the carrier (hereinafter also referred to simply as the "adsorption step"); The method includes at least a step of eluting the AAV mutant adsorbed to the adsorbent using an elution solution (hereinafter also simply referred to as the "elution step"); It is characterized by the following.
[0022] The AAV-binding protein, which is the ligand protein (protein immobilized on an insoluble carrier) of the AAV adsorbent used in the present invention, is not particularly limited as long as it is a polypeptide capable of binding to AAV, and examples thereof include laminin receptors such as integrins, anti-AAV antibodies, and AAV receptors (AAVR).
[0023] A preferred embodiment when the AAV binding protein is AAVR is a polypeptide selected from any one of (i) to (iii) below. (i) a polypeptide comprising at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or the amino acid residues from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1; (ii) A polypeptide having an amino acid sequence including at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, with the proviso that these amino acid residues include substitution, deletion, insertion, or addition of one or several amino acid residues at one or several positions, and having AAV-binding activity; (iii) A polypeptide comprising at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or the amino acid residues from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, and having 70% or more homology to an amino acid sequence consisting of these amino acid residues, and having AAV-binding activity.
[0024] SEQ ID NO: 1 is the full-length amino acid sequence of KIAA0319L (UniProt accession number: Q8IZA0, SEQ ID NO: 1), which is one embodiment of AAVR. The amino acid residues from serine (S) at position 312 to glutamic acid (E) at position 401 of SEQ ID NO: 1 correspond to the extracellular domain 1 (PKD1) of KIAA0319L, and the amino acid residues from isoleucine (I) at position 409 to aspartic acid (D) at position 500 of SEQ ID NO: 1 correspond to the extracellular domain 1 (PKD1) of KIAA0319L. corresponds to the extracellular domain 2 of KIAA0319L (PKD2).
[0025] Furthermore, when the AAV-binding protein is AAVR, a further preferred embodiment is a polypeptide comprising at least a region corresponding to PKD1 and PKD2 of KIAA0319L (SEQ ID NO: 1) (amino acid residues from serine (S) at position 312 to aspartic acid (D) at position 500 of SEQ ID NO: 1), specifically a polypeptide selected from any of the following (iv) to (vi): (iv) a polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO:1; (v) a polypeptide having an amino acid sequence including at least the amino acid residues from serine at position 312 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid sequence includes substitution, deletion, insertion, or addition of one or several amino acid residues at one or several positions within the amino acid residues at positions 312 to 500, and having AAV binding activity; (vi) A polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO:1, and having 70% or more identity to the amino acid sequence consisting of the amino acid residues at positions 312 to 500, and having AAV-binding activity.
[0026] The polypeptides shown in any of (i) to (vi) above need only contain at least a region corresponding to PKD1 and / or PKD2 of the above-mentioned KIAA0319L, and may, for example, contain all or a part of a region corresponding to other extracellular region domains (domain 3 (PKD3), domain 4 (PKD4) and domain 5 (PKD5)) located on the C-terminal side of PKD2, or may contain all or a part of a region corresponding to a signal sequence such as the MANSC (Motif At N terminus with Seven Cysteines) domain located on the N-terminal side of PKD1 or a cysteine-rich region, or may contain all or a part of a transmembrane region and an intracellular region located on the N-terminal and / or C-terminal side of the extracellular region.
[0027] Examples of (ii) and (v) include a polypeptide containing at least the amino acid residues from serine (S) at position 25 to aspartic acid (D) at position 213 of the amino acid sequences set forth in SEQ ID NOs: 7 and 9, and the AAV binding protein disclosed in WO2021 / 106882. Examples of the substitutions, deletions, insertions, or additions described in (ii) and (v) include the substitutions of amino acid residues disclosed in WO2021 / 106882.
[0028] In (ii) and (v), "one or several" varies depending on the position of the amino acid substitution in the three-dimensional structure of AAVR and the type of amino acid residue, but for example, it means 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1. The substitution of "one or several" amino acid residues may occur at positions other than the substitution of amino acid residues disclosed in WO2021 / 106882, for example, as long as it has AAV binding activity.
[0029] In addition, the "substitution of one or several amino acid residues" in (ii) and (v) may include, in addition to the amino acid substitution at the specific position described above, conservative substitution in which a substitution occurs between amino acids having similar physical and / or chemical properties. Conservative substitution is generally known to those skilled in the art to maintain the function of a protein between a substituted and unsubstituted one. Examples of conservative substitutions include substitution between glycine and alanine, between serine and threonine, or between glutamic acid and aspartic acid (Protein Structure and Function, Medical Science International, 9, 2005). In addition, the "substitution, deletion, insertion, or addition of one or several amino acid residues" in (ii) and (v) also includes naturally occurring mutations (mutants or variants) based on differences in the origin of AAVR, differences in species, etc.
[0030] The homology of the amino acid sequences in (iii) and (vi) may be 70% or more, and may be higher (e.g., 80% or more, 85% or more, 90% or more, or 95% or more). In this specification, "homology" may mean similarity or identity, and may particularly mean identity. "Homology of amino acid sequences" means homology with respect to the entire amino acid sequence. "Identity" between amino acid sequences means the ratio of amino acid residues of the same type in those amino acid sequences (Experimental Medicine, 31(3), Yodosha). "Similarity" between amino acid sequences means the sum of the ratio of amino acid residues of the same type in those amino acid sequences and the ratio of amino acid residues with similar side chain properties (Experimental Medicine, 31(3), Yodosha). The homology of amino acid sequences can be determined using an alignment program such as BLAST (Basic Local Alignment Search Tool) or FASTA.
[0031] In the present invention, the insoluble carrier used for immobilizing the AAV-binding protein described above is not particularly limited as long as it is insoluble in a sample containing AAV (such as a culture solution) and a solution used for analysis or purification (such as an elution solution, an equilibration solution, or a washing solution). Examples include carriers made from polysaccharides such as agarose, alginate (alginic acid salt), carrageenan, chitin, cellulose, dextrin, dextran, and starch, carriers made from synthetic polymers such as polyvinyl alcohol, polymethacrylate, poly(2-hydroxyethyl methacrylate), and polyurethane, and carriers made from ceramics such as silica. Among them, carriers made from polysaccharides and carriers made from synthetic polymers are preferred as insoluble carriers. Examples of the preferred carriers include polymethacrylate gels with hydroxyl groups introduced such as Toyopearl (manufactured by Tosoh Corporation), agarose gels such as Sepharose (manufactured by Cytiva Corporation), and cellulose gels such as Cellufine (manufactured by JNC Corporation). The shape of the insoluble carrier is not particularly limited, but is preferably one that can be packed into a column. For example, it may be any of granular, monolithic, membrane-like, and fibrous, and may be either porous or non-porous.
[0032] The AAV binding protein may be immobilized on the insoluble carrier, for example, via covalent bond. Specifically, for example, the AAV binding protein may be immobilized on the insoluble carrier by covalently bonding the insoluble carrier via an active group possessed by the insoluble carrier, thereby producing the AAV adsorbent used in the present invention. Examples of the active group include N-hydroxysuccinimide (NHS) activated ester group, epoxy group, carboxy group, maleimide group, haloacetyl group, tresyl group, formyl group, and haloacetamide group. For example, a commercially available insoluble carrier having an active group may be used as it is, or an active group may be introduced into the insoluble carrier. Examples of commercially available supports having active groups include TOYOPEARL AF-Epoxy-650M, TOYOPEARL AF-Tresyl-650M (both manufactured by Tosoh Corporation), HiTrap NHS-activated HP Columns, NHS-activated Sepharose 4 Fast Flow, Epoxy-activated Sepharose 6B (all manufactured by Cytiva Corporation), and SulfoLink Coupling Resin (manufactured by Thermo Fisher Scientific).
[0033] An example of a method for introducing active groups onto the support surface is a method in which one of a compound having two or more active sites is reacted with a hydroxy group, epoxy group, carboxy group, amino group, etc. present on the support surface.
[0034] Examples of compounds that introduce epoxy groups into hydroxyl groups or amino groups present on the carrier surface include epichlorohydrin, ethanediol diglycidyl ether, butanediol diglycidyl ether, hexanediol diglycidyl ether, and polyethylene glycol diglycidyl ether. Specific examples of polyethylene glycol diglycidyl ether include Denacol EX-810 (n=1), Denacol EX-811 (n=1), Denacol EX-850 (n=2), Denacol EX-851 (n=2), Denacol EX-821 (n=4), Denacol EX-830 (n=9), Denacol EX-832 (n=9), Denacol EX-841 (n=13), and Denacol EX-861 (n=22) (all manufactured by Nagase ChemteX Corporation).
[0035] Examples of compounds that introduce carboxy groups into epoxy groups present on the surface of the carrier include 2-mercaptoacetic acid, 3-mercaptopropionic acid, 4-mercaptobutyric acid, 6-mercaptobutyric acid, glycine, 3-aminopropionic acid, 4-aminobutyric acid, and 6-aminohexanoic acid.
[0036] Compounds for introducing maleimide groups into hydroxy groups, epoxy groups, carboxy groups, or amino groups present on the support surface include N-(ε-maleimidocaproic acid) hydrazide, N-(ε-maleimidopropionic acid) hydrazide, 4-(4-N-maleimidophenyl)acetic acid hydrazide, 2-aminomaleimide, 3-aminomaleimide, 4-aminomaleimide, 6-aminomaleimide, 1-(4-aminophenyl)maleimide, 1-(3-aminophenyl)maleimide, 4-(maleimido)phenyl isocyanate, 2-maleimidoacetic acid, 3-maleimidopropionic acid, Examples include succinimidyl-4-(maleimidomethyl)cyclohexane-1-carbonyl-(6-aminohexanoic acid), succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylic acid, (p-maleimidobenzoyl)N-hydroxysuccinimide ester, (m-maleimidobenzoyl)N-hydroxysuccinimide ester, and dextran.
[0037] Examples of compounds that introduce haloacetyl groups into hydroxyl groups or amino groups present on the surface of a carrier include chloroacetic acid, bromoacetic acid, iodoacetic acid, chloroacetic acid chloride, bromoacetic acid chloride, bromoacetic acid bromide, chloroacetic acid anhydride, bromoacetic acid anhydride, iodoacetic acid anhydride, 2-(iodoacetamido)acetic acid-N-hydroxysuccinimide ester, 3-(bromoacetamido)propionic acid-N-hydroxysuccinimide ester, and 4-(iodoacetyl)aminobenzoic acid-N-hydroxysuccinimide ester.
[0038] As a method for introducing active groups onto the carrier surface, an example is a method in which an ω-alkenylalkane glycidyl ether is reacted with a hydroxy group or an amino group present on the carrier surface, and then the ω-alkenyl moiety is halogenated with a halogenating agent to activate the group. Examples of the ω-alkenylalkane glycidyl ether include allyl glycidyl ether, 3-butenyl glycidyl ether, and 4-pentenyl glycidyl ether. Examples of the halogenating agent include N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide.
[0039] Another example of a method for introducing active groups onto the carrier surface is a method for introducing active groups onto carboxy groups present on the carrier surface using a condensation agent and an additive. Examples of condensation agents include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), dicyclohexylcarbodiamide, and carbonyldiimidazole. Examples of additives include NHS, 4-nitrophenol, and 1-hydroxybenztriazole.
[0040] The immobilization of the AAV binding protein to an insoluble carrier can be carried out, for example, in a buffer solution. Examples of the buffer solution include acetate buffer, phosphate buffer, MES (2-MorpholinoEthaneSulfonic acid) buffer, HEPES (4-(2-HydroxyEthyl)-1-PiperazineEthaneSulfonic acid) buffer, Tris (Tris (hydroxymethyl) aminomethane) buffer, and borate buffer. The reaction temperature during immobilization can be appropriately set depending on various conditions such as the reactivity of the active group and the stability of the AAV binding protein. The reaction temperature during immobilization may be, for example, 4°C or higher and 50°C or lower, and preferably 10°C or higher and 35°C or lower.
[0041] An example of the characteristic analyzed in the characteristic analysis step is the ability to infect a cell. In particular, when the AAV binding protein is an AAVR selected from any one of (i) to (vi), it is particularly suitable for analyzing the ability to infect a cell, and an AAV adsorbent comprising an insoluble carrier and the AAVR immobilized on the carrier is particularly useful for screening AAV mutants based on their infectivity.
[0042] In addition, when the AAV adsorbent is in the form of a column packed with the adsorbent (hereinafter, also referred to as "AAV adsorbent column"), it is preferable in that the characteristic analysis step can be easily performed. Hereinafter, one embodiment of the characteristic analysis step using an AAV adsorbent column will be described in detail.
[0043] A sample containing AAV can be added (applied) to the AAV adsorbent column using a liquid delivery means such as a pump. In this specification, adding a liquid to a column is also referred to as "delivering a liquid to a column." The sample containing AAV may be solvent-substituted using an appropriate buffer solution before being added to the AAV adsorbent column. In addition, before adding a sample containing AAV to the AAV adsorbent column (i.e., before the adsorption step), the AAV adsorbent column may be equilibrated using an appropriate buffer solution (equilibration solution). The equilibration is expected to enable, for example, AAV to be analyzed with higher accuracy. Examples of buffer solutions used for solvent replacement and equilibration include phosphate buffer, acetate buffer, succinate buffer, citrate buffer, Tris buffer, HEPES buffer, and MES buffer, which have buffering capacity in the neutral region (referring to a region of pH 4.0 to 9.0 in this specification). To such buffer solutions, for example, inorganic salts such as sodium chloride or calcium chloride at 10 mM to 600 mM may be added. The buffer solution used for the solvent replacement and the equilibration solution may or may not be the same. In addition, when components other than AAV, such as impurities, remain in the AAV adsorbent column after passing a sample containing AAV through the AAV adsorbent column, such components may be removed (washed) from the AAV adsorbent column before eluting the AAV adsorbed on the AAV adsorbent with an elution solution (i.e., before the elution step). Components other than AAV can be removed from the AAV adsorbent column, for example, by using an appropriate buffer solution as a washing solution. For the washing solution, for example, the description of the buffer solution used for solvent replacement or equilibration can be applied mutatis mutandis.
[0044] In the elution step, AAV is eluted with a gradient in order to elute the AAV based on the characteristics of the AAV. The gradient may be changed in two or more steps (stepwise) (step gradient), or may be changed with a linear gradient (linear gradient). An example of gradient elution is a gradient in which the pH is lowered from the neutral region described above to the acidic region (region more acidic than the neutral region described above). The pH of the eluate at the start may be in the neutral region described above, i.e., pH 4.0 to 9.0, and preferably pH 4.5 to 6.0. The acidic region, which is the pH of the eluate after the gradient, may be pH 3.5 or less, and preferably pH 2.0 to 2.5. There is no particular limit to the lower limit of the flow rate, and the upper limit depends on the back pressure of the insoluble carrier used in the AAV adsorbent. Typically, 0.5 mL / min to 2.0 mL / min is preferred. The gradient time may be any time that the difference in the characteristics can be identified as a difference in elution time, and is preferably 5 minutes or more, more preferably 20 minutes or more, and further preferably 45 minutes or more.
[0045] In the method of the present invention, the AAV that can be analyzed may be an AAV that exists in nature or an AAV that has been artificially created, such as AAV of each serotype (AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, etc.), AAV with amino acid substitutions, AAV fused with a peptide or protein, and AAV modified with a polymer.
[0046] According to the present invention, AAV mutants obtained from a mutant library of polynucleotides encoding AAV proteins can be screened based on the differences in the properties of the mutants. In particular, when the ligand of the AAV adsorbent used in the property analysis step is an AAVR selected from any one of (i) to (vi) above, AAV mutants can be screened based on the differences in their ability to infect cells, and therefore, by the screening method of the present invention, AAV with high infectivity that can be used as a gene therapy drug can be obtained with high efficiency. Moreover, unlike conventional methods, there is no need to sequentially purify candidate AAV mutants, and therefore AAV can be screened easily. EXAMPLES
[0047] Hereinafter, the present invention will be described in more detail using examples in which the AAV-binding protein is a polypeptide comprising at least an amino acid sequence corresponding to extracellular domain 1 or domain 2 of KIAA0319L; however, the present invention is not limited to these examples.
[0048] Example 1 Library construction by error-prone PCR A library was constructed by randomly introducing mutations into a plasmid containing a polynucleotide encoding the capsid protein of serotype 8 adeno-associated virus (AAV8) using error-prone PCR.
[0049] (1) Error-prone PCR was performed using the pRC8 vector (manufactured by Takara Bio) capable of expressing the capsid region VP1 (UniProt accession number: P03135, SEQ ID NO: 4) of AAV8 as a template. Error-prone PCR was performed by preparing a reaction solution having the composition shown in Table 1 or Table 2 using oligonucleotides consisting of the sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6 as PCR primers, heat-treating the reaction solution at 98°C for 2 minutes, and carrying out 40 cycles of reaction consisting of a first step at 98°C for 30 seconds, a second step at 60°C for 30 seconds, and a third step at 72°C for 40 seconds, and finally heat-treating at 72°C for 5 minutes.
[0050] [Table 1]
[0051] [Table 2]
[0052] (2) The PCR product obtained in (1) was purified and then ligated into the expression vector pRC8 by homologous recombination using an In-fusion reagent (Takara Bio).
[0053] (3) After the ligation reaction was completed, the reaction mixture was used to transform Escherichia coli DH5α strain, which was then cultured on a Luria-Bertani (LB) plate medium containing 100 μg / mL ampicillin (at 37°C for 18 hours). The colonies formed on the plate were used as a random mutant library.
[0054] (4) From the random mutant library (transformants) prepared in (3), several colonies were selected and inoculated into 2 mL of LB liquid medium containing 100 μg / mL ampicillin, and cultured overnight at 37°C with shaking in a test tube.
[0055] (5) Each plasmid was extracted from the culture medium of each colony using NucleoSpin Plasmid EasyPure (Mach-Liner Gel), and the polynucleotide region encoding the capsid region VP1 of AAV8 was subjected to sequence analysis.
[0056] As a result of sequence analysis, the error-prone PCR successfully introduced mutations into the polynucleotide encoding the capsid region VP1 of AAV8. The average mutation introduction rate was about 10 amino acid mutations per molecule when the reaction solution having the composition shown in Table 1 was used, and about 6 amino acid mutations per molecule when the reaction solution having the composition shown in Table 2 was used.
[0057] Example 2. Construction of libraries with mixed-base primers A library was constructed by selectively introducing mutations into specific sites by performing PCR using a plasmid containing a polynucleotide encoding the AAV8 capsid protein as a template and an oligonucleotide containing mixed bases as a primer.
[0058] (1) PCR was performed using a vector pRC8 vector (manufactured by Takara Bio) capable of expressing the capsid region VP1 (SEQ ID NO: 4) of AAV8 as a template, and a combination of oligonucleotides consisting of the sequences described in SEQ ID NO: 11 (Forward primer) and 12 (Reverse primer), a combination of oligonucleotides consisting of the sequences described in SEQ ID NO: 13 (Forward primer) and 14 (Reverse primer), and a combination of oligonucleotides consisting of the sequences described in SEQ ID NO: 15 (Forward primer) and 16 (Reverse primer). PCR was performed by preparing a reaction solution consisting of the composition shown in Table 3, heat-treating the reaction solution at 98 ° C for 2 minutes, performing 30 cycles of a first step at 98 ° C for 10 seconds and a second step at 72 ° C for 30 seconds as one cycle, and finally heat-treating at 72 ° C for 1 minute.
[0059] [Table 3]
[0060] (2) After purifying the PCR product obtained in (1), ligate it with the DNA Ligation Kit.<Mighty Mix> An intramolecular ligation reaction was carried out using a kit (Takara Bio).
[0061] (3) A random mutant library (transformants) was prepared by the method described in Example 1(3), and the polynucleotide region encoding the capsid region VP1 of AAV8 was sequenced by the methods described in Example 1(4) and (5).
[0062] As a result of sequence analysis, a mutation was introduced into the polynucleotide encoding the capsid region VP1 of AAV8 by the PCR. Hereinafter, the libraries constructed in Examples 1 and 2 are collectively referred to as the pRC8 library.
[0063] Example 3 Preparation of AAV vectors (1) A nucleotide sequence (SEQ ID NO: 3) was designed in which a restriction enzyme EcoRI recognition sequence (GAATTC) was added to the 5'-end of a polynucleotide encoding EGFP (Enhanced Green Fluorescent Protein) consisting of the amino acid sequence set forth in SEQ ID NO: 2, and a stop codon (TAG) and a BamHI recognition sequence (GGATCC) were added to the 3'-end.
[0064] (2) A polynucleotide consisting of the sequence set forth in SEQ ID NO:3 was totally synthesized and cloned into a plasmid (entrusted to FASMAC, named pUC-EGFP). E. coli JM109 strain was transformed with pUC-EGFP, and the resulting transformant was cultured. pUC-EGFP was extracted from the culture medium using a QIAprep Spin Miniprep kit (Qiagen).
[0065] (3) The pUC-EGFP obtained in (2) was digested with the restriction enzymes EcoRI and BamHI, and then ligated into the expression vector pAAV-CMV (Takara Bio Inc.) which had been previously digested with the restriction enzymes EcoRI and BamHI. The ligation product was used to transform the Escherichia coli JM109 strain.
[0066] (4) The transformant obtained in (3) was cultured overnight at 37°C with shaking in a 5 L baffled flask containing 1 L of 2YT medium (1.6% (w / v) Tryptone, 1% (w / v) Yeast Extract, 0.5% (w / v) Sodium Chloride) containing 100 μg / mL carbenicillin. After the culture was completed, the cells were collected by centrifugation, and a large amount of the EGFP-expressing vector pAAV-EGFP was prepared from the collected cells using a Plasmid Mega Kit (Qiagen).
[0067] (5) The Escherichia coli JM109 strain was transformed with the pRC8 library or the pRC8 vector (Takara Bio) and the pHelper vector (Takara Bio) constructed in Examples 1 and 2. The obtained transformants were used in the same manner as in (4) to prepare large quantities of the pRC8 library or the pRC8 vector and the pHelper vector.
[0068] (6) In a 250 mL Erlenmeyer flask (Corning) containing 60 mL of Viral Production medium (Thermo Fisher Scientific), Viral Production Cells (Thermo Fisher Scientific) were incubated at 3.0 × 10 in 8% (v / v) carbon dioxide at 37 °C. 6 The culture was shaken at 120 rpm until the cell density reached 100 cells / mL.
[0069] (7) Cell density is 3.0 × 10 6 When the cell count reached 1.0 cells / mL, AAV-MAX Enhancer (Thermo Fisher Scientific) was added at 1 / 10 the volume of the medium, and the medium was cultured for 1 hour under the same conditions as in (6). After that, 1 mL was dispensed into 24-well dishes (Corning).
[0070] (8) The pAAV-EGFP prepared in (4), the pRC8 library or pRC8 Vector and pHelper prepared in (5), and a mixture of AAV-MAX Transfection Reagent, Viral Plex Complexation, and AAV-MAX Transfection Booster (all manufactured by Thermo Fisher Scientific) were added to the culture medium obtained in (7) to carry out gene transfer, and the cells were cultured with shaking at 120 rpm for 3 days under conditions of 8% (v / v) carbon dioxide and 37°C.
[0071] (9) To the culture medium obtained in (8), AAV-MAX Lysis Buffer (Thermo Fisher Scientific) was added in an amount of 1 / 10 of the medium, Benzonase (Merck Millipore) was added at a final concentration of 1 U / mL, and magnesium chloride was added at a final concentration of 2 mM, and the cells were disrupted by shaking at 120 rpm at 37°C for 2.0 hours.
[0072] (10) After the cells were lysed, the solution was centrifuged at 8,000 × g and 4 ° C for 10 minutes, and the supernatant was passed through a filter with a pore size of 0.22 μm to remove floating matter, thereby obtaining a solution containing AAV8 or its mutant.
[0073] Example 4 Preparation of AAV binding proteins (1) The E. coli BL21(DE3) strain was transformed with the plasmid pET-AVR11a containing a polynucleotide (SEQ ID NO: 8) encoding a polypeptide comprising the AAV binding protein AVR11a consisting of the amino acid sequence set forth in SEQ ID NO: 7, or the plasmid pET-AVR21 containing a polynucleotide (SEQ ID NO: 10) encoding a polypeptide comprising the AAV binding protein AVR21 consisting of the amino acid sequence set forth in SEQ ID NO: 9, to obtain a transformant capable of expressing AVR11a or AVR21. The transformant was inoculated into 3 mL of 2YT liquid medium containing 50 μg / mL kanamycin and pre-cultured overnight at 37° C. under aerobic shaking. In SEQ ID NOs: 7 and 9, the region from the 1st methionine (M) to the 22nd alanine (A) is the PelB signal peptide, the region from the 25th serine (S) to the 213th aspartic acid (D) is the AAV binding protein (AVR11a or AVR21), and the histidines (H) from the 214th to the 219th are the histidine tag. AVR11a is a polypeptide in which the amino acid substitutions shown in (I) to (XI) below have occurred in the extracellular domain 1 (PKD1) and domain 2 (PKD2) (amino acid residues from the 312th serine (S) to the 500th aspartic acid (D) of SEQ ID NO: 1) of the AAV receptor KIAA0319L, and AVR21 is a polypeptide in which the amino acid substitutions shown in (I) to (XXI) below have occurred in the PKD1 and PKD2. (I) Valine at position 317 of SEQ ID NO: 1 (position 30 of SEQ ID NO: 7 and 9) is replaced with aspartic acid (II) Tyrosine at position 342 of SEQ ID NO: 1 (position 55 of SEQ ID NO: 7 and 9) is replaced with serine (III) Lysine at position 362 of SEQ ID NO: 1 (position 75 of SEQ ID NO: 7 and 9) is substituted with glutamic acid (IV) Lysine at position 371 of SEQ ID NO: 1 (position 84 of SEQ ID NO: 7 and 9) is substituted with asparagine (V) Valine at position 381 of SEQ ID NO: 1 (position 94 of SEQ ID NO: 7 and 9) is substituted with alanine (VI) Isoleucine at position 382 of SEQ ID NO: 1 (position 95 of SEQ ID NO: 7 and 9) is substituted with valine (VII) Glycine at position 390 of SEQ ID NO: 1 (position 103 of SEQ ID NO: 7 and 9) is substituted with serine (VIII) Lysine at position 399 of SEQ ID NO: 1 (position 112 of SEQ ID NO: 7 and 9) is substituted with glutamic acid (IX) Serine at position 476 of SEQ ID NO: 1 (position 189 of SEQ ID NO: 7 and 9) is substituted with arginine (X) Asparagine at position 487 of SEQ ID NO: 1 (position 200 of SEQ ID NO: 7 and 9) is substituted with aspartic acid (XI) Alanine at position 330 of SEQ ID NO: 1 (position 43 of SEQ ID NO: 7 and SEQ ID NO: 9) is substituted with valine (XII) Asparagine at position 324 of SEQ ID NO: 1 (position 37 of SEQ ID NO: 9) is substituted with histidine (XIII) Valine at position 326 of SEQ ID NO: 1 (position 39 of SEQ ID NO: 9) is substituted with alanine (XIV) Glutamine at position 334 of SEQ ID NO: 1 (position 47 of SEQ ID NO: 9) is replaced with leucine (XV) Glutamic acid at position 335 of SEQ ID NO: 1 (position 48 of SEQ ID NO: 9) is replaced with valine (XVI) Substitution of threonine at position 341 of SEQ ID NO: 1 (position 54 of SEQ ID NO: 9) with alanine (XVII) Phenylalanine at position 379 of SEQ ID NO: 1 (position 92 of SEQ ID NO: 9) is replaced with tyrosine (XVIII) Lysine at position 380 of SEQ ID NO: 1 (position 93 of SEQ ID NO: 9) is substituted with arginine (XIX) Lysine at position 467 of SEQ ID NO: 1 (position 180 of SEQ ID NO: 9) is substituted with glutamine (XX) Serine at position 482 of SEQ ID NO: 1 (position 195 of SEQ ID NO: 9) is substituted with threonine (XXI) Asparagine at position 492 of SEQ ID NO: 1 (position 205 of SEQ ID NO: 9) is substituted with aspartic acid (2) 2 mL of the preculture solution from (1) was inoculated into 200 mL of 2YT liquid medium containing 50 μg / mL kanamycin in a 1 L baffled flask, and cultured aerobically at 37°C with shaking.
[0074] (3) After 2.0 hours from the start of the culture, the medium was cooled on ice, IPTG (IsoPropyl-β-D-ThioGalactopyranoside) was added to a final concentration of 0.1 mM, and the medium was subsequently cultured aerobically with shaking at 25° C. overnight.
[0075] (4) After the cultivation was completed, the culture medium was centrifuged at 8,000 rpm at 4° C. for 20 minutes to collect the bacterial cells.
[0076] (5) The cells collected in (4) were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole at 5 mL / 1 g (cells), and then disrupted using an ultrasonic generator (Insonator 201M [Kubota Shoji Co., Ltd.]) at 8° C. for about 10 minutes at an output of about 150 W. The disrupted cell solution was centrifuged twice at 8,000 rpm for 20 minutes at 4° C., and the supernatant was collected.
[0077] (6) The supernatant obtained in (5) was applied to an XK26 / 20 column (manufactured by Cytiva) packed with 50 mL of Ni Sepharose 6 Fast Flow (manufactured by Cytiva) that had been previously equilibrated with Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole (hereinafter also referred to as "equilibration solution A"). After washing with equilibration solution A, the column was eluted with 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.
[0078] (7) The eluate obtained in (6) was dialyzed against 20 mM Tris buffer (pH 7.4) containing 150 mM sodium chloride to prepare the AVR11a and AVR21 proteins required for producing the AAV adsorbent.
[0079] Example 5 Preparation of AAV adsorbent (1) A hydrophilic vinyl polymer for separating agents (Toyopearl, manufactured by Tosoh Corporation) was prepared as an insoluble carrier, and a carrier was prepared by introducing iodoacetamide groups by chemically modifying the hydroxyl groups on the polymer surface.
[0080] (2) To 2 g (wet weight) of the carrier prepared in (1), 8 mg of the AAV binding protein AVR11a or AVR21 prepared in Example 4 and TCEP (Tris(2-CarboxyEthyl)Phosphine) at a final concentration of 0.3 mM as a reducing agent were added, and the mixture was allowed to react by shaking for 3 hours under conditions of pH 8.1 and 25° C. In this way, AVR11a-immobilized gel, which is an AAV adsorbent in which AVR11a is immobilized, and AVR21-immobilized gel, which is an AAV adsorbent in which AVR21 is immobilized, were prepared.
[0081] Example 6 AAV analysis using AAV adsorbent (1) 1.25 mL of the AVR11a immobilized gel and AVR21 immobilized gel, which are the AAV adsorbents prepared in Example 5, were packed into empty stainless steel columns (φ4.6 mm×75 mm, manufactured by Tosoh Corporation) to prepare columns. Hereinafter, the column packed with the AVR11a immobilized gel is referred to as the AVR11a column, and the column packed with the AVR21 immobilized gel is referred to as the AVR21 column.
[0082] (2) The AVR11a column or AVR21 column was connected to an HPLC M40A (Shimadzu Corporation) and equilibrated with 10 mM glycine buffer (pH 6.0) containing 0.01% (w / v) Tween 20 (trade name), 50 mM calcium chloride, and 15 mM sodium acetate (hereinafter also referred to as "equilibration solution B").
[0083] (3) 0.1 mL of the solution containing the AAV8 mutant obtained in Example 3 was applied to each column equilibrated in (2).
[0084] (4) After washing with equilibration solution B at a flow rate of 0.5 mL / min for 30 minutes, 10 mM glycine buffer (pH 2.0) containing 0.01% (w / v) Tween 20 (trade name), 50 mM calcium chloride, and 15 mM sodium acetate (hereinafter also referred to as "elution solution A") and equilibration solution B were pumped to each column so as to obtain a linear gradient in which the elution solution A concentration went from 0% to 100% in 60 minutes (flow rate of 0.5 mL / min). After the linear gradient was completed, elution solution A was pumped for 5 minutes, and then equilibration solution B was pumped again to each column for re-equilibration.
[0085] (5) The AAV8 mutants eluted from each column were detected by fluorescence intensity at 350 nm with excitation light at 280 nm, and the time at the apex of the elution peak corresponding to the AAV8 mutant was determined as the elution time of the AAV8.
[0086] Table 4 shows the results (elution times) of adsorption / elution of the Q452R / N471D amino acid substituted variant, which is one embodiment of the AAV8 mutants obtained in Examples 1 and 3, the T265H amino acid substituted variant, the G267N amino acid substituted variant, and the G268S amino acid substituted variant, which are one embodiment of the AAV8 mutants obtained in Examples 2 and 3, and wild-type (unsubstituted) AAV8 onto the AAV adsorbent.
[0087] It can be seen that all of the AAV8 mutants evaluated in this example (Q452R / N471D amino acid substitution, T265H amino acid substitution, G267N amino acid substitution, and G268S amino acid substitution) have shorter elution times than wild-type AAV8.
[0088] [Table 4]
[0089] Example 7 Large-scale preparation of AAV vectors To evaluate infectivity, the AAV8 mutant vectors evaluated in Example 6 (Q452R / N471D amino acid substitution, T265H amino acid substitution, G267N amino acid substitution, and G268S amino acid substitution) were prepared in large quantities.
[0090] (1) Viral Production Cells (Thermo Fisher Scientific) were cultured by the method described in Example 3(6).
[0091] (2) Gene introduction was performed by adding a mixture of AAV-MAX Enhancer (manufactured by Thermo Fisher Scientific), pAAV-EGFP prepared in Example 3(4), the vector containing the polynucleotide encoding the AAV8 mutant prepared in Example 3(5), pHelper, and AAV-MAX Transfection Reagent, Viral Plex Complexation, and AAV-MAX Transfection Booster (all manufactured by Thermo Fisher Scientific), and the cells were cultured with shaking at 120 rpm for 3 days under conditions of 8% (v / v) carbon dioxide and 37°C.
[0092] (3) The cells in the culture medium obtained in (2) were disrupted by the method described in Example 3(9), and a solution containing the AAV8 mutant was obtained by the method described in Example 3(10).
[0093] (4) The solution obtained in (3) was previously equilibrated with 20 mM Tris-HCl buffer (pH 8.0) containing 0.5 M sodium chloride (hereinafter referred to as "equilibration solution C"). The solution was applied to a 7 mL POROS AAVX column (Thermo Fisher Scientific) equilibrated with 100% ethanol.
[0094] (5) After washing with equilibration solution C, elution was performed with 0.1 M acetate buffer (pH 2.5) containing 0.5 M sodium chloride. The resulting eluate was neutralized by adding 1 / 4 volume of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride to obtain the AAV8 mutant vector solution.
[0095] (6) The vector concentration in the solution obtained in (5) was quantified by qPCR using the AAVpro Titration Kit (Takara Bio).
[0096] Example 8: Evaluation of infectivity of AAV8 mutants The ability to infect cells was evaluated using the AAV8 mutant vectors (Q452R / N471D amino acid substitution, T265H amino acid substitution, G267N amino acid substitution, and G268S amino acid substitution) prepared in large quantities in Example 7.
[0097] (1) Based on the qPCR quantification results in Example 7(6), the AAV8 mutant vector genome (VG) concentration was set to 5.0 × 10 10 Adjusted to VG / mL.
[0098] (2) Place HEK293T cells (Thermo Fisher Scientific) at 5.0 × 10 in each well of a 24-well multiplate (Corning). 5 500 μL of each was seeded at a concentration of 1.0 × 10 cells / mL and cultured for 24 hours. After culture, the cell count was measured and the number of cells was 5.0 × 10 5 Confirmed that it was / well.
[0099] (3) After culturing in (2), 100 μL of the vector solution prepared in (1) was added to the well and cultured at 37°C for 24 hours. That is, the number of AAV infections per HEK293T cell was 1.0 × 10 4 It becomes VG.
[0100] (4) After the incubation in (3), the culture supernatant from each well was collected in a tube. After washing the wells with phosphate-buffered saline (PBS), 100 μL / well of cell detachment solution TrpLE (Thermo Fisher Scientific) was added and incubated at 37°C for 1 minute to detach the cells attached to the wells.
[0101] (5) The culture supernatant collected in (4) was added to the well to stop the detachment process, and the culture supernatant was then returned to the tube, which was used as a detection solution.
[0102] (6) After suspending the detection solution (5) several times with a pipette, the fluorescence intensity derived from EGFP expressed in each cell was measured using Guava easyCyte (Luminex). The proportion of cells with enhanced fluorescence intensity was measured compared to cells to which the AAV infection solution was not added, and the proportion of cells infected with the AAV8 mutant vector (infection rate) was calculated.
[0103] As a result of comparing AAV infection rates, when the infectivity of wild-type AAV8 was taken as 100%, the infectivity of the AAV8 mutants was significantly reduced, with the Q452R / N471D amino acid substitution mutant at 31.6%, the T265H amino acid substitution mutant at 47.1%, the G267N amino acid substitution mutant at 32.7%, and the G268S amino acid substitution mutant at 24.4%. The AAV8 mutants with weak infectivity also had weak binding strength to the AAV adsorbent, and therefore were presumably eluted from the AAV adsorbent earlier than the wild-type AAV8.
[0104] From the above results, it can be seen that AAV mutants can be screened based on their ability to infect cells by analyzing their characteristics using a method that includes at least the steps of adsorbing the AAV mutant to an AAV adsorbent comprising an insoluble carrier and a polypeptide containing at least an amino acid sequence corresponding to extracellular domain 1 or domain 2 of KIAA0319L immobilized on the carrier, and eluting the AAV mutant adsorbed to the adsorbent using an elution solution.
Claims
1. introducing mutations into a polynucleotide encoding an adeno-associated virus (AAV) protein to construct a library of said polynucleotide variants; Culturing a transformant obtained by transforming a host with the library to express AAV mutants; and analyzing the characteristics of the AAV mutant, The analyzing step includes a step of adsorbing the AAV mutant to an AAV adsorbent comprising an insoluble carrier and an AAV binding protein immobilized on the carrier; The method further comprises at least a step of eluting the AAV mutant adsorbed to the adsorbent using an elution solution.
2. 2. The method of claim 1, wherein the property is the ability to infect a cell and the AAV binding protein is a polypeptide selected from any of the following: (i) a polypeptide comprising at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or the amino acid residues from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1; (ii) a polypeptide having an amino acid sequence including at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, with the proviso that these amino acid residues include substitution, deletion, insertion, or addition of one or several amino acid residues at one or several positions, and having AAV binding activity; (iii) A polypeptide comprising at least the amino acid residues from serine at position 312 to glutamic acid at position 401 or from isoleucine at position 409 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, and having 70% or more homology to an amino acid sequence consisting of these amino acid residues, and having AAV-binding activity.
3. 3. The method of claim 2, wherein the AAV binding protein is a polypeptide selected from any of the following (iv) to (vi): (iv) a polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO:1; (v) a polypeptide having an amino acid sequence including at least the amino acid residues from serine at position 312 to aspartic acid at position 500 of the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid sequence includes substitution, deletion, insertion, or addition of one or several amino acid residues at one or several positions in the amino acid residues at positions 312 to 500, and having AAV binding activity; (vi) A polypeptide comprising at least the amino acid residues from the 312th serine to the 500th aspartic acid of the amino acid sequence set forth in SEQ ID NO: 1, and having 70% or more homology to the amino acid sequence consisting of the amino acid residues from the 312th to the 500th amino acid residues, and having AAV-binding activity.
4. The method according to any one of claims 1 to 3, wherein the AAV adsorbent is in the form of a column packed with the adsorbent.
